Skip to main content
SpringerLink
Log in

Practical Considerations and Complex Cases in Psoriasis

  • Chapter
  • First Online:
Biologic and Systemic Agents in Dermatology

  • 1478 Accesses

Abstract

This chapter describes several case scenarios a health-care provider may encounter when treating patients with psoriasis. In several instances, there are no official guidelines when such situations are encountered. The management of the following case reports are recommendations and opinion suggested by the author when such complex circumstances arise. Where there are multiple choice options, alternative answers different from the selected one would be clinically appropriate and comparable. It is important to understand that abiding by the package information for the medication is paramount when the situation becomes unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Armstrong AW, Bagel J, van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151:432–8.

    Article  PubMed  Google Scholar 

  2. Costanzo A, Talamonti M, Botti E, Spallone G, Papoutsaki M, Chimenti S. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. Dermatology. 2009;219:48–53.

    Article  CAS  PubMed  Google Scholar 

  3. Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. J Am Acad Dermatol. 2016;75:612–8.

    Article  CAS  PubMed  Google Scholar 

  4. Patel S, Patel T, Kerdel FA. The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature. Int J Dermatol. 2016;55:487–93.

    Article  PubMed  Google Scholar 

  5. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat. 2009;20:100–8.

    Article  CAS  Google Scholar 

  6. Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Grimaud JC, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B; Groupe d'Etude Thérapeutique des affections Inflammatoires du tube Digestif. Subcutaneous Ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 14:242–50.

    Google Scholar 

  7. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70:401.e1–14.

    Article  CAS  Google Scholar 

  8. Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Rev Clin Immunol. 2015;11:709–20.

    Article  CAS  PubMed  Google Scholar 

  9. Zarei M, Villada G, Romanelli R. Biologics therapy in psoriasis patients with viral hepatitis, HIV, and cardiovascular diseases. J Am Acad Dermatol Suppl. 2016;74:3532.

    Google Scholar 

  10. Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016;74:974–80.

    Article  CAS  PubMed  Google Scholar 

  11. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, Van Voorhees AS, Armstrong AW, Siegel M, JJ W. From the Medical Board of the National Psoriasis Foundation: perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2016;75:798–805.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. David Geffen School of Medicine at UCLA, Dermatology Institute and Skin Care Center, 2001 Santa Monica Blvd Suite 1160W, Santa Monica, CA, 90404, USA

    Paul S. Yamauchi MD, PhD

Authors
  1. Paul S. Yamauchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul S. Yamauchi MD, PhD .

Editor information

Editors and Affiliations

  1. Division of Dermatology, David Geffen School of Medicine a UCLA, Los Angeles, California, USA

    Paul S. Yamauchi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Yamauchi, P.S. (2018). Practical Considerations and Complex Cases in Psoriasis. In: Yamauchi, P. (eds) Biologic and Systemic Agents in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-66884-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-66884-0_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-66883-3

  • Online ISBN: 978-3-319-66884-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation